Ipsen to acquire Memo Therapeutics in €700M+ deal
Key Facts
In a move that bolsters its presence in the biotechnology sector, Ipsen (IPN.PA) announced the acquisition of Memo Therapeutics in a deal valued at over €700 million, according to reports. The acquisition aims to strengthen Ipsen's pipeline with Memo Therapeutics' assets, though full strategic details were not disclosed.
Ipsen shares closed at €168.80 on June 30, 2026, with a trading range of €164.80 to €169.10 (per market data). The deal comes amid notable M&A activity in the biotech industry, as larger players seek to enhance their pipelines with innovative therapies.
Investors are now focused on financing details and anticipated regulatory approvals, particularly from antitrust authorities. The deal's progress could influence Ipsen's share performance going forward, with the possibility of competing bids emerging. Markets will also watch for further announcements regarding Ipsen's growth strategy.
Latest Updates · 2
- Notable·
Update: On July 1, 2026, Ipsen clarified that the deal includes a first-in-class BK polyomavirus antibody (potravitug) for serious post-transplant infection with no currently approved targeted treatments. The deal is underpinned by Phase II (SAFE KIDNEY II) results that support initiation of a pivotal Phase II/III trial later this year, expanding Ipsen's rare disease portfolio.
- Notable·
Update: Ipsen revealed that the deal targets potavitug, a Phase II clinical-stage antibody for BK polyomavirus-associated nephropathy in kidney transplant patients. The drug received FDA Fast Track designation in May 2023 and EU Orphan Drug Designation in December 2025, underscoring its clinical significance.